Mark A. F. Kendall (BE PhD FTSE FRSA FNAI) (born 1972) is an Australian biomedical engineer, inventor, scientist and entrepreneur.

He is Founder and CEO of WearOptimo Pty Ltd^[1] and the Vice-Chancellor's Entrepreneurial Professor at the Australian National University.^[2]

Kendall was formerly the Professor of Biomedical Engineering at the University of Queensland, where he led a team at the Australian Institute for Bioengineering and Nanotechnology^{[citation needed]}. He was Founder, CTO and a Director of Vaxxas^{[citation needed]}. Prior to this, in the UK, he was a University Research Lecturer at the University of Oxford and a lecturer at Magdalen College, Oxford^{[citation needed]}. Whilst at Oxford, Kendall was Associate Director of the PowderJect Research Centre for Gene and Drug Delivery^{[citation needed]}.

Kendall serves at the co-chair of the $150 million Australian Stem Cell Therapies Mission^[3] and on the World Economic Forum Global Future Council on Biotechnology.^[4]

Kendall has filed more than 160 patents (including territories)^{[citation needed]}, published in excess of 300 papers^{[citation needed]}, licensed his technologies seven times (including to Merck & Co.)^{[citation needed]} and partnered globally, including with the World Health Organization, and the Bill & Melinda Gates Foundation.^[5] The biotech enterprises he has founded or made significant contribution to have generated in the region of $2 billion Aus in value^{[citation needed]}.

Kendall's contributions to innovation in global healthcare has been recognised with more than forty awards. These include recent elections as:

• World Economic Forum Technology Pioneer (2015).^[6]

• Fellow of ATSE; Australian Academy of Technological Sciences and Engineering (2017).^[7]

• Fellow of the Royal Society for the encouragement of Arts, Manufacture and Commerce (now the RSA), UK; (2017)^{[citation needed]}.

Kendall is a CSL Young Florey Medallist^[8] and Rolex Laureate.^[9][10]

Kendall's work regularly features in international media, including on the National Geographic Channel.^[11]

Kendall's TedGlobal talk has been viewed more than a million times.^[12]

https://www.ted.com/speakers/mark_kendall

Kendall was born on 16 April 1972.^[13] He received his Bachelors of Engineering (Hons I, 1993) and PhD (1998) from the University of Queensland.^[14]

In 1998, Kendall moved to the UK to take up a position in the Department of Engineering Science at the University of Oxford (1998-2006). He has subsequently held positions at the University of Queensland (2006-2018)^{[citation needed]} and at the Australian National University (2018–Present)^{[citation needed]}.

Kendall has over 160 patent applications of which^{[citation needed]}, 128 have been granted to date^{[citation needed]}. He has authored more than 300 refereed papers^{[citation needed]}.

At the University of Oxford^[14] (1998-2006) Kendall developed a biolistic technique for the delivery of vaccines directly into the skin without the use of needles.

At the University of Queensland (2006-2018) Kendall invented the Nanopatch^[15][16] for needle-free delivery of vaccines.^[17][18]

At WearOptimo^[19] and the Australian National University^[20] (2018 to present), Kendall has invented the Microwearable™^[21][22] sensor for personalised medicine.

During his career, Kendall has collaborated with major global health partners including the Bill & Melinda Gates Foundation,^[23] World Health Organization^[24][25] and Merck & Co.^[26]

He is an Australian Government Academy of Science COVID-19 Expert.^[27]

• Elected to the World Economic Forum Global Future Council on Biotechnology (2019 to present).^[28]
• Elected Fellow of the Australian Academy of Technology and Engineering ATSE (2017).^[7]
• Elected Fellow of the Royal Society for the encouragement of Arts, Manufacture and Commerce (now the RSA), UK (2017)^{[citation needed]}.
• Elected to the World Economic Forum Global Future Council on Entrepreneurship and Innovation (2016-2018)^{[citation needed]}.
• CSL Young Florey Medal (2016).^[29][30][31]
• Dr John Dixon Hughes Medal for Medical Research Innovation (2016).^[32]
• World Economic Forum Technology Pioneer (2015).^[33]
• Rolex Laureate Award for Enterprise (2012) for his "pioneering efforts to expand knowledge and improve human life".^[34]
• 2011 Australian Innovation Challenge winner.^[35]
• 2011 Eureka Prize for Interdisciplinary Research.^[35]
• 2010 Merck Translational Research Excellence Commercialisation Award.^[36]
• 2005 Best Medical Innovation Award (Popular Science magazine)^{[citation needed]}.
• Younger Engineer of Great Britain (2004).^{[citation needed]}

As Associate Director of the Oxford University PowderJect Research Centre (2000-2006)^{[citation needed]}, Kendall advanced biolistics technology^{[citation needed]}, commercialised with PowderJect^{[citation needed]}, purchased by Chiron (later Novartis) in 2003^{[citation needed]}; and then with PowderMed, purchased by Pfizer in 2006^{[citation needed]}.

Kendall founded Vaxxas in 2011 to advance his Nanopatch^[15] technology for global impact, securing more than $40 million of investment, in the series A ($15m)^[37] and B (in excess of $25m) rounds.^[38] The Nanopatch technology has been licensed to Merck & Co. He served as the Vaxxas Chief Technology Officer, Director, and Chair of the Vaxxas Advisory Board (2011-2015).

In 2018, Kendall founded WearOptimo^[39] where he serves as CEO.